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Dysbindin is known to (a) bind ß-dystrobrevin in postsynaptic densities in a number of brain areas, and (b) be a component of the biogenesis of lysosome-related organelles complex 1 (BLOC-1). Reduced levels of dysbindin have been identified presynaptically at hippocampal formation sites lacking ß-dystrobrevin in schizophrenia cases. This suggests a role for dysbindin in schizophrenia pathobiology independent of the ß-dystrobrevin complex and therefore possibly involving the BLOC-1 complex. As dysbindin is a susceptibility gene for schizophrenia, we considered the remaining 7 BLOC-1 genes as suitable candidate genes for association analysis. BLOC-1 consists of proteins encoded by at least 8 genes -- dysbindin, MUTED, PLDN, CNO, SNAPAP, BLOC1S1, BLOC1S2 and BLOC1S3. Functional regions of all genes were subjected to mutation detection analysis using DHPLC. Polymorphic markers identified were supplemented with additional SNPs from dbSNP. All markers (n=50) were typed in a sample of 92 individuals to elucidate LD structure and inform on choice of markers (n=29) for analysis in our full sample of 373 schizophrenia cases and 812 controls. Evidence of association was detected with single markers at BLOC1S2 (p = 0.05) and BLOC1S3 (p = 0.003). We are currently testing our associated SNPs in a large independent replication sample. Should our results replicate independently it would suggest a role for BLOC-1 in schizophrenia etiology.

Autism is a relatively common neurodevelopmental disorder characterized by impaired social interaction and communication, and repetitive and stereotyped behaviours and interests. It occurs in around 1 in every 1000 births, has an onset in the first three years after birth, and persists throughout life. There is a strong yet complex genetic component and since the biological basis of the disorder is unknown, much research is focused on the identification of susceptibility genes. Several groups have identified associations between autism and a wide area of chromosome 2q, suggesting a predisposing gene or genes to autism within the 2q region. We have previously reported a patient with high-functioning autism, who has a small but cytogenetically visible *de novo* translocation 46,XY, ins(9;2)(q31.1;q32.2q31.3). The chromosome 2q31.3-q32.2 region falls within the above linkage findings. This would appear to be the smallest known deletion of this part of chromosome 2, suggesting that the region includes a predisposing gene or genes for autism.

UBE2E3, a gene encoding a ubiquitin-conjugating enzyme, lies just 3kb from the proximal breakpoint of this translocated region. This gene seemed, therefore, to be a good candidate for mutational screening for variants that may increase the risk of developing autism. We performed sequencing analysis on the 5 coding exons and intronic flanking sequences of UBE2E3 in probands from 77 Irish autism families. As a result of this analysis we have identified two sequence variants comprising an apparently synonymous SNP (T/A) in exon 2 and a change of a G to a T at the +5 position in intron 6. While other studies are required, our results to date appear to reduce the likelihood that UBE2E3 has a role in the aetiology of autism.

The aetiology of short stature is largely unknown. The Short HOmeoboX (SHOX) containing gene located on the pseudoautosomal region of the sex chromosomes has been implicated in short stature, including Turner syndrome (TS). Heterozygous and homozygous deletions of SHOX result in Leri-Weill dyschondrosteosis (LWD) and Langer dysplasia (LD) respectively. The clinical features of Madelung deformity, short fourth metacarpals and high arched palate are common to these three conditions. LWD is further characterised by disproportionate short stature and mesomelic shortening of the forearm and lower leg.

We report a large four-generation Northern Irish pedigree, with seven clinically affected individuals. The proband was referred with learning difficulties and short stature. Both parents and extended families had significant short stature. Examination of the proband and his mother suggested a clinical diagnosis of LWD, confirmed by radiological findings. In other less clinically affected relatives, radiology was needed to confirm the diagnosis. SHOX gene mutation screening in mother and son has demonstrated a heterozygous deletion.

Phenotypic heterogeneity, a recognised feature of LWD, is extensively observed in our pedigree. The use of radiological investigation in apparently clinically unaffected individuals is important. Investigation of short stature is essential, even if present in both parents.

Introduction
============

Low-density lipoprotein (LDL) oxidation by leukotrienes and the 5-lipoxygenase activating protein (FLAP) plays a central role in atherosclerosis. A four single nucleotide polymorphism (SNP) haplotype (HapB) in the gene encoding FLAP has been shown to be associated with myocardial infarction (Helgadottir *et al*. Nature Genetics, 2004). Within HapB, SNP SG13S114 has been shown to be associated with stroke (Lohmussaar *et al.* Stroke, 2005). We investigated HapB in an Irish study group with premature ischaemic heart disease (IHD).

Methods
=======

1494 individuals (580 families) were included. 10 individuals (3 families) were excluded due to insufficient DNA, leaving 799 discordant sib-pairs and 62 parent-child trios. Linkage disequilibrium between HapB and IHD was tested using the combined transmission disequilibrium test and pedigree disequilibrium test.

Results
=======

SNP SG13S377 was excluded as it showed no heterogeneity in our study group. The numbers of informative families for SG13S114, SG13S41 and SG13S35 were 271, 79 and 127, respectively. A significant association between the informative SNPs of HapB and IHD was detected (p=0.032) due to the preferential transmission of the T allele of SG13S114 (p=0.015).

Conclusions
===========

Using family-based association tests we have shown association between the FLAP gene (particularly SG13S114) and IHD. Replication of previous work suggests an important role for FLAP in the pathogenesis of atherosclerosis.

Breast cancer is the most common cause of cancer-related deaths for women in Ireland. While it is estimated that between 5 and 10% of breast cancers may be due to inherited predisposition involving mutations in BRCA1 and BRCA2, the role of these genes in Irish breast cancer families is as yet unknown. As a result of a HRB-funded research initiative from 1998--2002, a total of 362 breast/ovarian cancer patients selected on the basis of early onset disease and/or a family history of breast/ovarian cancer, have been recruited by two Centres in Dublin. These patients have received screening for mutations in BRCA1 and BRCA2. Of these patients, 280 have received a partial screen (exon 11 PTT of both genes, cDNA PTT and dHPLC); while an additional 82 patients have received comprehensive mutation screening of BRCA1 and BRCA1 by bi-directional sequencing, together with a limited deletion screen.

To date, deleterious mutations have been identified and characterised in 33 patients. The spectrum of deleterious gene alterations identified comprises nonsense (BRCA1: 2, BRCA2: 4), frameshift (BRCA1: 9, BRCA2: 11), splice-site (BRCA1: 1, BRCA2: 1) and missense (BRCA1: 0, BRCA2: 2) mutations. Two recurrent mutations have been identified, namely BRCA1 E143X \[c.546G_T\] and BRCA1 c.1294_1333del40, found in 13 and 4 unrelated patients respectively. Based on these findings, 161 unaffected family members have received predictive testing at the NCMG to date.

We present details of these results and assess the information generated in terms of incidence of BRCA1 and BRCA2 mutations in Irish breast cancer families and the clinical criteria used to select them. We also consider the family-wide implications of providing a BRCA1 and BRCA2 mutation screening service to these patients. Results of mutation analysis in this cohort of patients will provide useful information should a diagnostic service providing mutation screening of BRCA1 and BRCA1 be implemented in the Republic of Ireland.

Natural antisense transcripts (NATs) have been implicated in many aspects of eukaryotic gene expression including genomic imprinting. The 11p15.5 region harbors 3 imprinted sense/antisense transcript pairs, IGF2/IGF2AS(PEG8), KvLQT1/KvLQT1AS(LIT1) and SLC22A1L/SLC22A1LS. SLC22A1L(Solute-carrier-family-22(organic-cationtransporter),member-1-like), displays preferential expression of the maternal allele in foetal samples; with polymorphic imprinting in adult tissue. SLC22A1LS shares 31bp with SLC22A1L, is also maternally expressed in fetal tissue, but its imprinting status in adult tissue remains elusive. This study investigated the imprinting phenotype of SLC22A1L/SLC22A1LS in a cohort of benign and malignant breast tissues. SLC22AIL DNA-PCR-RFLP analysis using *Nla* III restriction digestion and 6% PAGE evaluation, identified SLC22A1L heterozygotes within the cohort (n=89). Commercial sequencing (MWG) identified informative SLC22A1LS samples. Random-hexamer primed cDNA synthesis (Superscript TmII) followed by SLC22A1L/SLC22A1LS specific RTPCR, and imprinting evaluation by commercial sequencing (MWG) demonstrated that SLC22A1LS, displays a non imprinted profile in reduction mastectomy cases (n=6). However, for SLC22A1L 1/4 (25%) of reductions showed a gain of imprinting (GOI). In the malignant cohort, GOI was also demonstrated in 18.2% for SLC22A1L and 15% for SLC22A1LS. One case demonstrated GOI at both loci concomitantly. Novelly, this study reports the imprinting status of SLC22A1LS in adult tissue, and highlights a common epigenetic alteration affecting gene expression at these paired loci.

Progression to androgen independent (AI) prostate cancer (PC) can take approximately 18 months and is poorly understood.

Although epidemiological studies show that shorter GGC repeat in exon 1 of the androgen receptor (AR) confers a higher risk of PC, there is no information of GGC repeat status in androgen dependent (AD) & AI patients with PC.

The aim was to compare GGC repeat numbers in patients where PC is initially AD and progresses to AI state.

Eleven patients with AD PC underwent a second trans-urethral resection of prostate when their PC became AI. Pure population of benign & tumor cells were isolated from paraffin tissue blocks using Laser capture micro-dissection. The GGC repeat was amplified by nested PCR and repeat number was determined using ABI 3100 genetic analyzer and genescan software.

Three out of 11 patients (27%) had shortening of the GGC repeat by 7, 9 & 15 repeats in the AI PC compared to their benign cells and AD PC.

GGC shortening in AI PC suggests an alteration occurring in the AR gene with androgen ablation, and could explain the development of AI PC in certain patients. This finding may be clinically significant in early detection of AI phenotype.

HNPCC is an autosomal dominant cancer predisposition syndrome, characterised by colorectal adenocarcinoma, with or without extracolonic cancers. It is estimated that HNPCC may be responsible for ∼ 1--4 % of all colorectal cancers. Diagnosis of the syndrome is complex, both from a clinical and laboratory perspective. Clinically, because sporadic colorectal cancer is common, selection of possible HNPCC families for mutation screening is performed using the 'Amsterdam Criteria' (based on specific family history and early age (\<50yr) of onset). In the laboratory, a complex multidisciplinary approach is required, as there are several large genes, with a wide mutation spectrum, responsible for HNPCC, often with mutations unique to a family.

HNPCC is caused by germline mutations in DNA mismatch repair (MMR) genes, with mutations in MLH1, MSH2 and MSH6 accounting for ∼ 95 % of those found. Inactivation of MMR genes leads to a failure in repairing DNA replication errors, which can be detected as microsatellite instability (MSI) in tumour DNA and is highly characteristic of HNPCC, with 90-95 % of HNPCC tumours displaying MSI. Immunohistochemistry (IHC) using monoclonal antibodies to etermine the expression of MMR gene protein products in tumour tissue can indicate which specific gene to screen.

Large genomic rearrangements, such as whole exon deletions or duplications in MLH1 and MSH2 can account for 6--10 % of HNPCC mutations. These can be detected by multiplex ligation dependent probe amplification (MLPA).

Where MSI is found and/or IHC indicates loss of MMR protein(s), analysis by MLPA and/or mutation screening of the MLH1 and MSH2 genes by denaturing high performance liquid chromatography (dHPLC) and/or direct DNA sequencing is undertaken.

We have investigated over 50 Irish families, referred to the National Centre for Medical Genetics, suspected of having HNPCC. Through applying this complex and multidisciplinary approach, complete or partial mutation screening has been carried out on 29 patients and germline mutations in MMR genes have been identified and a diagnosis of HNPCC confirmed in 11 patients to date.

The genetic disorders Haemochromatosis (*HFE*), Cystic Fibrosis (*CFTR*), Phenylketonuria (*PAH*), Galactosaemia (*GALT*) and Homocystinuria (*CBS*) have a higher incidence in Ireland than elsewhere in Europe. In an investigation of the Northern Ireland population, a representative cohort of 900 anonymous DNA samples (150 × 6 counties) in the form of newborn screening 'Guthrie' cards was collected with appropriate ethical approval and genotyped for ten common mutations associated with these disorders: C282Y, H63D (*HFE*); G551D, R117H, DF508 (*CF*); R408W, F39L, I65T (*PAH*); Q188R (*GALT*); G307S (*CBS*). Some variation was observed between counties (and in some cases between genders) for individual mutations; however, these differences did not attain significance on statistical testing. The eastern counties (Antrim, Down and Armagh) exhibited lower carrier frequencies for several mutations compared with the western counties (Derry, Tyrone and Fermanagh); eg: the R408W *PAH* mutation. In direct contrast to the literature, the *CFTR* mutation R117H exhibits a higher carrier frequency to that of G551D (1 in 251 versus 1 in 884).

Single Nucleotide Polymorphisms (SNPs) found on the paternally-inherited Y-chromosome are used by human population geneticists to trace human lineages. Unlike autosomal markers, Y chromosome haplotypes are uniparentally inherited and therefore useful in untangling historic human migration patterns. Y chromosome markers also have the advantage of being passed from father to like surnames, allowing for the comparison of cultural and genetic inheritance. Ireland\'s relatively recent colonization by modern humans, coupled with its relative geographic isolation, makes it an ideal location for surname/Y-chromosome comparative study. Earlier work focused in the Republic of Ireland has shown the majority of Irish males (\>98% in Connaught) belong to a single haplotype, R1b1 (within the haplogroup PR\*). By contrast, a sample of the modern Norse population contains only 23% R1b1. This work suggests the possibility to distinguish genetically groups of Irish-Gaelic and putative Viking (Norse) origin. We have begun typing 197 buccal swabs from men in Northern Ireland for 10 SNP markers on the Y chromosome. Preliminary results show little difference in men with Irish-Gaelic surnames: 39 of 42 samples in haplogroup PR\* and 3 of 42 in haplogroup GJ\*, and those with Norse surnames (57 of 62 in PR\* and 5 of 62 in GJ\*).

The common Phenylketonuria mutation in Europe, R408W, is observed on chromosomes of two distinct haplotypes as the result of recurrent mutation: the two lineages are referred to as R408W-2.3 and R408W-1.8. Spatial autocorrelation analysis of their frequency distributions suggests that R408W-2.3 was dispersed across central and eastern Europe by human migration while R408W-1.8 arose in Ireland with limited subsequent spread \[O\' Donnell *et al*, *Eur J Hum Genet* 2002, **10**: 530-538; Tighe *et al*, *Hum Mutat* 2003, **21**: 387-393\].

Three novel dinucleotide Short Tandem Repeat (STR) markers within and flanking the human Phenylalanine Hydroxylase locus were identified and used to assess relative levels of genetic diversity within the R408W lineages. Phylogenetic analysis based upon STR haplotypes produced unrooted star-like networks demonstrating comparable levels of diversity for R408W-2.3 and R408W-1.8. Both networks were centred on a major haplotype \[61% of R408W-1.8 alleles; 49% of R408W-2.3 alleles\] and contained a total of 17 mutational steps. Estimates of allele age based upon intra-allelic variation generated values of 4,850 -- 37,975 yBP for R408W-1.8 and 7,700 -- 44,050 yBP for the R408W-2.3 mutation. Neutrality tests suggested that the two R408W lineages increased in frequency over time due to population expansion rather than heterozygote advantage.

A single population test (Ewens-Waterson test) applied in a genomic context was used to investigate the presence of recent positive selection in the Irish population. Several lines of evidence suggest that the Irish population has a relatively undisturbed genetic heritage which dates to the Paleolithic (pre-farming era). We first recognize outlier SNPs (23), from previously published data, with high F[st]{.smallcaps} branch specification in a European-American population. We then identified those, from the 23 SNPs, which were within or close to known genes. The presence of selection was then investigated through additional genotyping of microsatellites flanking these outlier SNPs. The results were also assessed in the context of a genome--wide distribution of the Ewens-Watterson\'s statistic, designed for the Irish population, to capture the effect of the population\'s unique demographic history. The signature of selection was detected in 5 genes out of 6 associated with outlier SNPs. The gene PKCη (protein kinase C, eta) show the most extreme signature of positive selection. The two microsatellites within this gene are in linkage disequilibrium, although they are 79 kb apart. Moreover, the cystic fibrosis gene (CFTR), a disease which has the highest worldwide frequency in Ireland, was among the genes showing evidence of selection.

It has been postulated that biological function may influence the degree to which allele frequencies at a locus differ among geographical populations. In order to evaluate this effect, genotypic data from re-sequencing studies of cytokine, cytokine receptor, cell adhesion molecule, Toll-like receptor and coagulation genes from public databases were analysed for genetic differentiation (F~ST~) between population samples of European and African descent. There was no difference among observed levels of differentiation when F~ST~ was calculated as a weighted average from all variants of each gene. However, when a corresponding analysis was performed using only non-synonymous (functional) variants for each gene, median Fst values among gene classes were statistically different (P = 0.0424). Interestingly, functional classes also differed statistically in the number of SNPs which are non-synonymous (P = 0.0278). Particularly high levels of differentiation were shown by individual non-synonymous SNPs at some Toll-like receptors, which encode components of the innate immune response, and *ICAM1*, the rhinovirus receptor. Variation in natural selection in different geographical regions may have inflated inter-population differentiation at these loci. Consequently, studies of genetic susceptibility to disease, using protein variants which potentially interact with pathogens, are more likely to be confounded by population admixture.

The human *MTHFD1* gene encodes a trifunctional cytoplasmic enzyme involved in folate metabolism and plays an important role in the biosynthesis of DNA. A polymorphism, R653Q, in MTHFD1 has previously been identified as a risk factor for neural tube defects (NTDs) in the Irish population. Characterisation of the *MTHFD1* promoter will lead to an understanding of how this gene is regulated and will provide an insight into how this gene influences NTD risk.

Analysis of the *MTHFD1* upstream region to date shows that this promoter lacks both a TATA box and an Initiator element. Transcriptional initiation has been identified at multiple start sites over a 120bp initiation window adjacent to the translation start site, using the 5\'RLM-RACE method. Many putative regulatory elements have been identified in the promoter region, including Sp1, E2F, and USF sites, which may be important in both initiation and control of transcription. An upstream region of 594bp has been shown to induce a high level of gene expression, which is significantly decreased when this region is reduced to 393bp. Putative Sp1 and E2F elements, located in the 200bp between these regions, are believed to be necessary for activated transcription of the *MTHFD1* gene.

TSC is an autosomal dominant multisystem disorder characterised by hamartomas in major organs of the body. The age of onset of symptoms can range from infancy to adulthood, with a variable degree of expression.

We present a 55-year-old lady referred via dermatology, with a four-year history of multiple periungual fibromas affecting her toenails and fingernails. She had a facial rash consistent with adenoma sebaceum. She had seizures in childhood and had a brain lesion removed in 1962 at the age of 12. She has had no seizure activity since and is of normal intelligence.

Clinical examination and investigations confirmed a diagnosis of TSC. There were bilateral renal cysts on ultrasound and enhanced CT of brain revealed calcified subependymal nodules. A mutation, 1210insT, was identified in exon 10 of the TSC1 gene.

The patient has one daughter who is asymptomatic. Her granddaughter, born in October 2002, developed seizures at 9 months of age, but has no physical or radiological evidence of TSC. Further investigation is underway to establish this child\'s TSC status.

Molecular identification of mutations responsible for TSC is a valuable adjunct to clinical and radiological investigation of family members of affected individuals.

Previously we reported linkage of dominantly inherited keratoconus with cataract to chromosome 15q and excluded several positional candidate genes by PCR-based sequencing. Large deletions and duplications are normally missed by this method, but can be detected by quantitative methods such as MLPA. MLPA is based on hybridisation and ligation of two adjacent primers which include different universal primers on opposite ends, permitting simultaneous amplification of several ligated sequences. One fluorescently labelled universal primer allows the products of differing size to be quantified.

We performed long range PCR of multiple exons of candidate genes in family members of the keratoconus with cataract pedigree, and detected no length variation. Next we interrogated the primer binding sites using MLPA and found one biased result inferring deletion in a candidate gene. The method was controlled using an X-linked marker, which showed the expected ratios in DNA from XY, XX and XXX patients.

Deletions may be responsible for about 10% of all pathogenic mutations. They may be difficult to detect, but should be considered in high priority candidate genes before proceeding to screen low priority candidates. MLPA is a straightforward method for identifying most deletions or duplications, but not rearrangements that do not affect dosage.

The high mortality of congenital diaphragmatic hernia (DH) is due to the presence of abnormalities of other organ systems that commonly co-exist. Antenatal identification of isolated DH allows selection of these infants for delivery in specialist centres to facilitate curative surgery. Certain patterns of associated abnormality are commonly found and can be assessed by ultrasound.

In our series of 52 cases of DH born in the National Maternity Hospital, 15 babies were stillborn, 18 died in the early neonatal period and 21 were transferred for surgery. 1 neonatal death did not have autopsy. A very high rate of associated major congenital malformation was identified in stillbirths and early neonatal deaths.

Abnormalities fell into 3 main groups: neural tube defects (NTDs), major cardiac defects(CHD) and chromosomal abnormalities(CA). Of 15 stillbirths, 8 had NTDS, 8 had CHDs, 5 were shown to have numerical chromosomal abnormalities and 2 had DH only. Of 18 neonatal deaths, 2 had NTDs, 5 had CHDs, 3 were shown to have CA (including 1 case of PallisterKillian Syndrome), there were six with other malformation syndromes and 6 with DH only.

As the number of Fragile X families identified continues to grow, the spectrum of phenotypes associated with particular genotypes becomes less clear. We describe a female patient (Patient A) with a family history of Fragile X, whose brother was identified as having a full Fragile X mutation. Patient A\'s mother and maternal grandmother were both found to have expansions in the premutation range. Patient A is a healthy 18 year old, pursuing third-level education, who presented to Gynaecology having had only 3 menstrual periods between the ages of 15 and 16. Gynaecology confirmed Premature Ovarian Failure (POF) and subsequent molecular analysis showed a full Fragile X mutation. POF has been described as being "unique to the premutation range" (∼ 20% of premutation females) but has never been associated with a full Fragile X mutation. Conversely, we describe a female patient (Patient B), who presented to the genetics clinic with a family history of Fragile X, having two nephews with full Fragile X mutations. She reported that she had learning difficulties from an early age and was unable to complete secondary school. She was found to have a small premutation (78 repeats +/−1). Case A raises the question of whether POF can also be associated with full Fragile X mutations, while case B may support recent evidence for mild clinical involvement in premutation carriers, or is it possible that mosaicism is clouding the Fragile X genotype-phenotype correlation.

Mutations in the CHD7 gene were associated with CHARGE syndrome in 2004. We present a sister and brother with clinical features of CHARGE syndrome who have a confirmed 2520G\>A (W840X) mutation. The parents have also had analysis of CHD7 and the father is a mosaic carrier of the mutation.

This 14 year-old girl was born at 39 weeks gestation to non-consanguineous Caucasian parents. At birth she had abnormal ears, pulmonary stenosis and a VSD. Later she presented with seizures, and was noted to have congenital dislocation of the hip, developmental delay, facial and limb asymmetry, conductive deafness, choanal narrowing, and thoracic kyphosis. Her 11 year-old brother was born at 38 weeks gestation. He had very similar features with abnormal cup-shaped ears, ASD and VSD, facial asymmetry, dysplastic capital femoral epiphyses, micropenis, absent testes and developmental delay. Both children have absent punctae and bilateral choroidoretinal colobomata. Initially, autosomal recessive inheritance was considered, along with the possibility of gonadal mosaicism. The parents have two other clinically unaffected children. Confirmation of the molecular genetic basis of CHARGE syndrome in this family has added to our knowledge of the condition and allowed more accurate counselling and risk estimation for the family.

Establishing the pathogenicity of missense mutations detected in a proband of Hereditary Non Polyposis Colorectal Cancer (HNPCC) families is a recurring problem for diagnostic laboratories. Here we consider two Northern Irish families who meet Amsterdam Criteria for HNPCC, who have been shown by the CAPP study to carry a missense mutation in the MLH1 gene.

The proband of Family 1 was shown to carry a c.302G\>A transition (G101D) in MLH1 exon 3. This mutation occurs within an ultra-conserved region of MLH1, disruption of this motif is predicted to disrupt ADP/ATP binding, resulting in a functionless protein. This mutation was not detected in over 160 population-matched control chromosomes. Family studies have shown that all five HNPCC-affected individuals are heterozygous for this mutation. Two-point linkage analysis (FASTLINK) of disease phenotype and G101D gave a maximum LOD score of 1.91 at theta=0, further supporting the association of the mutation with HNPCC in this family. This is to our knowledge the first report of this mutation.

The proband of Family 2 was shown to carry a c.2146G\>A transition (V716M) in MLH1 exon 19. This mutation is in a poorly conserved region of MLH1 and was not detected in over 150 population-matched control chromosomes. Two affected family members have been studied but only one carries the mutation. The mutation has been previously reported in the literature.

In conclusion, we provide evidence of a low allele frequency of the G101D and V716M mutations within our normal population. We have shown co-segregation of G101D with an HNPCC phenotype through family studies and we propose a possible mechanism of disease. In contrast, we have failed to determine a disease mechanism for the V716M mutation and family studies throw doubt on its pathogenicity.

We have chosen to exploit the hypoxic nature of prostate tumours to gain a therapeutic advantage. Gene therapy targeted to hypoxic tumour cells will allow selective killing of malignant cells.

The induction of gene expression under hypoxic conditions is governed by the activation of hypoxia-inducible factor 1 and its subsequent binding to hypoxia response elements (HREs). HREs are found in the promoter of various oxygen-responsive genes, including vascular endothelial growth factor (VEGF) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH).

We propose to use arrangements of increasing copy number of the HRE core sequence isolated from the VEGF and GAPDH promoter to drive the expression of the cytosine deaminase (CD) gene. CD is a prodrug activation enzyme, which converts inactive 5-fluorocytosine (5-FC) to active 5-fluorouracil (5-FU), allowing selective killing of vector containing cells. Hypoxic cells transfected with these constructs would express CD and therefore would be killed when treated with 5-FC.

A series of expression vectors were constructed which contain arrangements of 2, 5, 6 or 8 copies of the GAPDH or VEGF HREs. These constructs were transfected into 3 prostate cancer cell lines (DU145, PC-3, 22Rv1) and were tested for their efficacy when exposed to oxygen concentrations of 0.1% for 24 hours.

We present a case of partial trisomy 11 resulting from an interchromosomal insertion. A newborn male infant was initially referred with dysmorphic facies, saddle nose, low set ears, inspiratory stridor, short neck, micropenis, hypotonia and a wide interdigital cleft between the great toes. A genetic assessment further revealed redundant neck skin, a carp like mouth, epicanthic folds, strabismus, retrognathia and tapering fingers. The infant also required tube feeding. Subsequent development was severely delayed in all areas. At age 16, he was unable to walk, had no speech and had epilepsy controlled with sodium valproate. Chromosome analysis of cultured lymphocytes revealed an unbalanced 46,XY, der(2)ins(2;11) (q32.2; q23.1q25), t(10;13)(q24.3; q14.3) karyotype. The mother previously had 3 early miscarriages and one liveborn normal female. Examination of parental chromosomes revealed that the derivative chromosome 2 had been inherited from the mother who carried the balanced form of the insertion. The t(10; 13) translocation found in the infant had arisen de novo and was not felt to carry a major contribution to the overall phenotype. This infant has clinical features overlapping with partial trisomy 11q syndrome. Trisomy 11q syndrome is a rare but recognized syndrome and our case is interesting because it has arisen from an interchromosomal insertion. This appears to be the first case of trisomy 11q arising from an interchromosomal insertion.

The incidence of cystic fibrosis (CF) at birth in the Republic of Ireland is 1 in 1461. Since 1995, CF testing has been performed at our Centre by an ARMS method that has been designed to detect the 11 most common mutations in this population, at a sensitivity of 93%. To date, we have used this method to test 2729 patients who either have classical CF that has been diagnosed clinically, or who have symptoms suggestive of CF. Our ARMS test has provided a confirmatory genotype in 730 of these patients (approximately 27%). Following further clinical assessment, a cohort of 122 probable CF patients in whom one or no mutation had been identified by the ARMS method, were selected for further analysis. Mutation screening of the CFTR gene was performed by DGGE, dHPLC and sequencing initially to identify small gene alterations, followed by QMPSF (quantitative multiplex PCR of short fluorescent fragments) to identify large genomic rearrangements.

This additional analysis has so far resulted in the identification of a second CFTR gene alteration in 31/122 patients, and the identification of both CFTR gene alterations in 1/122 patients. Six of the CFTR gene alterations have not been reported previously, and in four of these cases, the pathogenicity is uncertain. Six CF mutations were detected in more than one apparently unrelated individual.

We present details of these findings and assess their contribution to the CF mutation spectrum of the population of the Republic of Ireland. We also report unusual cases involving the identification of a de novo mutation in one family and the identification of a CFTR deletion spanning exons 2, 3 and 4 in three apparently unrelated families.

Plans for newborn screening for cystic fibrosis (CF) and issues of sensitivity and efficiency with our current "home-brew" ARMS™ assay led us to look for a multiplexed CF assay which could be adapted to the mutation spectrum of the Irish population. We have an excellent knowledge of the Irish mutation spectrum, as all patients with mutations not detected by our ARMS assay are screened by DHPLC of the entire CFTR gene at the laboratory of Professor Claude Ferec in Brest, France. We are currently evaluating the Ambion Signature™ CF 2.0 ASR. This assay involves single-tube/well multiplex amplification followed by direct hybridisation of amplified products to allele specific capture probes without intervening purification steps or secondary amplification. Products are then measured by Luminex^100^ IS xMAP™ Technology.

To date, we have evaluated the core 29-target assay on a large cohort of DNA samples of known genotype, from different tissue sources, to examine sensitivity and specificity of the ASR. Results of these studies, as well as an analysis of cost and efficiency, will be presented.

Substantial differences between Eastern and Western regions have been a recurring finding in investigations of Irish population variation, most notably in the paternally inherited Y-chromosome. These differences have often been attributed to the preferential migration of post-foundation settlers to eastern regions of the island due to the relative proximity of Britain and Europe. Under this scenario Britain and the West of Ireland represent migration source and destination populations respectively, with the eastern region a zone of contact and admixture between the two. The impact and signature of any such process on the autosomal (biparentally inherited) genome was examined using intra-Ireland classical gene frequencies in a European context, and secondly in 380 autosomal microsatellites, typed in 194 British and Irish individuals, and analysed using both traditional genetic distance and model-based clustering approaches. No general or extensive longitudinal pattern of variation was detected. The apparent contrast with the Y chromosome and agreement with the maternally inherited mtDNA suggests that Y-chromosome differentiation was driven and exaggerated by male specific behaviours during or before Ireland\'s population history. However a fuller assessment of Irish autosomal regional variation will probably require larger samples sizes and greater knowledge of wider European variation at individual loci.

Loss of the adhesion protein E-cadherin occurs frequently in TCCB and is integral to development of the epithelialmesenchymal transition (EMT). CTNNA3 is one of a small family of catenins whose interaction allows the association of other catenins to cadherins. Importantly, CTNNA3 is downregulated in EMT, hypothetically compromising E-cadherin associated cell-cell adhesion. The objectives of this current study are: To investigate the imprinting status and phenotype of alpha T-catenin in a cohort of primary bladder cancer samples and matched paired normal samples.To establish if alpha T-catenin is subject to loss of heterozygosity (LOH).

Using primers to a published transcribable SNP in exon 12, (Van Dijk *et al,* 2004), CTNNA3 specific DNA and cDNA PCR products were amplified, purified and commercially sequenced to identify informative cases. (MWG). Of the cohort so far examined, 40% of samples were heterozygous, with one paired case displaying LOH. CTNNA3 was also shown to display gain of imprinting (GOI). CTNNA3 loss through LOH or epigenetic downregulation could play a key role in rendering cells less adherent to each other thereby favouring a more metastatic phenotype. Reference: Van Dijk *et al* 2004 PMID:15533819.

Maple Syrup Urine Disease (MSUD) is an autosomal recessive metabolic disorder caused by a deficiency in activity of the branched-chain keto acid dehydrogenase (BCKD) complex, and occurs with an incidence of 1:125000 in Ireland; it is one of the five disorders screened for as part of the newborn screening programme in Ireland. Mutations in the human BCKD genes, E1α(BCKDHA), E1ß(BCKDHB), E2(DBT) and E3(DLD) result in MSUD and are known as Type Ia, Ib, II and III respectively.

This study seeks to establish the mutation spectrum associated with MSUD in Irish patients by means of a PCR-based exon sequencing strategy. Preliminary data, from 7 patients has demonstrated three type II mutations in the E2 sub-unit. The first, found in two siblings, is a single base pair deletion 81_83del in exon 5 resulting in a frameshift which introduces a premature stop codon predicting a loss of at least 50% of the mRNA transcript. The second, found in two independent cases, is a G\>C transversion in exon 10 resulting in substitution of alanaine with proline. The third is a splice-site mutation in intron 9. Additional intronic SNPs have been detected and these are currently being investigated as to their functional relevance.

Background
==========

The *MTHFD1* gene encodes a trifunctional enzyme that plays a central role in folate metabolism. Maternal folate status and/or homocysteine levels have been implicated in a range of pregnancy complications, most notably in pregnancies affected by a neural tube defect (NTD). We have previously identified the R653Q polymorphism in MTHFD1 as a maternal risk factor for NTDs.

Aim
===

The aim of this study was to initially confirm the association of the MTHFD1 R653Q polymorphism as a maternal risk factor for NTDs in the Irish population and also to consider whether the MTHFD1 R653Q polymorphism had a role to play in other pregnancy complications.

Results
=======

We have confirmed the association between the MTHFD1 'QQ' genotype and maternal NTD risk in a second cohort of women from the Irish population (OR 1.49 (95% CI 1.07--2.09), P = 0.02). We also found that the MTHFD1 'QQ' genotype is a significant risk factor for severe abruptio placentae (OR 2.85 (95%CI 1.47-5.53), P = 0.002) but not for pre-eclampsia (OR 1.44 (95%CI 0.78--2.67) P = 0.25).

Tetrasomy 9p is a rare chromosome syndrome with less than forty cases reported in the literature. Previously described cases have a fairly recognizable phenotype comprising multiple craniofacial, limb and cardiac abnormalities. It is suggested that presence or absence of mosaicism has an effect on phenotypic differences and mortality rates. Nonmosaic tetrasomy 9p cases have poor prognosis. We report a new case of de novo nonmosaic tetrasomy 9p with multiple dysmorphic features. Our case was a full term IUGR female infant who survived for ten days. The dysmorphic features included brachycephaly, broad nasal root, prominent forehead, wide sutures, large anterior fontanel, micrognathia, micropthalmia, grossly hyperextended lower limbs, bilateral hip dislocations, small toes, a skin tag over chest, overlapping fingers and hypoplastic nails. The infant also had cardiac anomalies, Dandy Walker malformation and a partially septate uterus. Skeletal survey revealed 11 pairs of broad ribs, platyspondyly, poor acetabular and femoral head development and absent patellae. Chromosome analysis of peripheral lymphocytes and fibroblasts revealed nonmosaic tetrasomy 9p. The clinical features of our case, compared with cases reported in the literature give an additional support to the emerging phenotype of this chromosomal syndrome.

Trisomy 10p is a rare syndrome with a variable phenotype. The most commonly described clinical features of trisomy 10p are mental retardation, proportionate growth retardation, hypotonia, microcephaly, bossing of forehead, dysplastic ears, high arched or cleft palate, nose abnormalities, and club foot. Most cases result from familial balanced translocation. Pure and de novo cases are rare. We describe a case of de novo partial trisomy 10p with clinical features suggestive of facio-auriculovertebral spectrum. The clinical features include hemifacial microsomia, external ear atresia, ear tags, and normal physical and mental development. These clinical findings have not been described in previously reported cases of trisomy 10p.

Retinitis pigmentosa (RP) is a group of inherited retinopathies that gradually results in blindness due to degeneration of the retina. The rod and cone photoreceptors found in the retina are responsible for the conversion of light into electrical impulses, which are then transmitted to the brain via the optic nerve. However in RP patients, these photoreceptors deteriorate over time until the ability to transmit electrical messages is lost. RP can be inherited in an autosomal dominant, autosomal recessive, x-linked recessive or digenic fashion. In addition, mutation within mitochondrial DNA can also cause RP. RP is genetically heterogeneous with 29 genes being identified in disease pathology to date. Furthermore, RP is also characterised by intragenic heterogeneity where many different mutations within a given gene are responsible for causing the disease in different families.

The gene that is responsible for the RP10 form of autosomal dominant retinitis pigmentosa (adRP) has been mapped to human chromosome 7q31.1, and accounts for 5--10% of all RP cases in the US and Europe. In our lab, comparative analysis of the transcriptional profiles within the retina of mice carrying a targeted disruption of the rhodopsin gene identified the gene encoding inosine monophosphate dehydrogenase 1 (IMPDH1) as a candidate gene for RP10. In addition, several studies have also revealed that specific mutations within IMPDH1 segregate with RP affected families (Kennan A *et al.* *Hum Mol Genet* 2002: **11:** 547-558), thus providing further evidence that mutations in IMPDH1 are the cause of the RP10 form of adRP. Structural protein analysis have indicated that mutant IMPDH1 protein misfolding or aggregation is the likely cause of severe retinopathy in human (Ahern A *et al.* *Hum MolGenet*2004; **13:** 614-650). In contrast, IMPDH1 ^−/−^ mice at four months of age, which is equivalent to a teenage human subject, have shown no structural or functional degeneration in the retina. This observation suggests that the dominant segregation pattern associated with RP10 is not caused by haploinsufficiency of normal IMPDH1 gene, but the disease pathology is caused by a dominant negative phenotypic effect exerted by mutant protein.

The collective findings summarised above represent RP10 as a potential target for therapeutic intervention where simultaneous ablation of wild type and mutant IMPDH1 transcripts by siRNA molecules may alleviate the severe retinopathy of RP10 by prolonging the survival of photoreceptor neurons.

The risk of developing Coeliac Disease is determined by interactions between environmental factors and multiple contributing loci. Microsatellite repeat markers studies in affected Italian sib-pairs have indicated linkage between the 5q31-33 region and Coeliac Disease. We sought to investigate this region for extra-genic evolutionarily conserved regions (ECRs) which may be indicative of gene regulatory sequences. ECRs were identified using ECR Browser by comparing orthologous sequences from human and mouse. SNPs within Transcription Factor Binding Sites (TFBS) may result in altered gene expression, thus we sought to identify polymorphic TFBS within ECRs and determine whether specific polymorphisms are associated with disease pathology.

The ECR browser is linked to dbSNPs, allowing identification of SNPs within selected sequences. ECRs containing SNPs were analysed via rVISTA2.0. However, TFBS identified solely on resemblance to consensus binding sequences results in the generation of large numbers of false positive results. rVISTA2.0 reduces the false positive TFBS identification rate by identifying conserved TFBS via comparison of orthologous sequences from two species (in this case mouse and human) with regard to sequence identity and relative position. 34 SNPs were identified which altered conserved putative TFBS over 1Mb, a frequency of 1/29.4Kb. These sites are being evaluated for disease association.

Triploidy, the most frequent chromosomal abnormality in first trimester spontaneous miscarriages is estimated to occur in 2% of human conceptions. A true incidence of diploid/triploid mosaicism is difficult to obtain. Severe intrauterine growth retardation, facial or body asymmetry, asymmetric digit syndactyly, characteristic facial dysmorphism, abnormal male genitalia and mental retardation are characteristic features.

Three cases are presented:

*Case 1:* A history of intrauterine growth retardation, postnatal chest infections and feeding difficulties were noted. Profound hypotonia, facial and body asymmetry, asymmetric digit syndactyly, thoracic scoliosis, facial dysmorphism and a pigmented skin area were observed. Skin chromosomes were reported as 69, XXY\[9\]/46, XY\[21\] at 5 months.

*Case 2:* Truncal obesity, facial and foot asymmetry, dysmorphism with asymmetric toe syndactyly and microgenitalia were observed. Skin chromosomes were reported as 69, XXY\[16\]/46, XY\[14\] at 8 years.

*Case 3:* A history of poor tone, learning difficulties, truncal obesity, facial dysmorphism, kyphoscoliosis and asymmetric toe syndactyly were observed. Skin chromosomes were reported as 69, XXY\[17\]/46, XY\[15\] at 15 years.

This diagnosis should be considered in all individuals with truncal obesity, syndactyly and asymmetry. We could not demonstrate any correlation between level of triploid mosaicism and phenotype.

Multiplex Ligation-Dependent Probe Amplification (MLPA) is a novel method employed to detect copy number aberrations of several nucleic acid sequences in a single reaction. Deletions and amplifications of a gene, or part thereof, are not detected by sequence analysis of Polymerase Chain Reaction (PCR) amplified gene fragments as a normal copy is still present. MLPA provides a faster, more robust and efficient method than Fluorescent In Situ Hybridisation (FISH), allowing up to 45 specific sequences to be amplified simultaneously with the use of only one pair of PCR primers. In this study we have used MLPA to screen for subtelomeric abnormalities in 105 patients with unknown causes of mental retardation (MR). Subtelomeric abnormalities are responsible for 5% to 10% of unexplained MR cases. The P070 Telomere Kit, from MRC™ Holland, was employed for this procedure. This kit includes probes for each autosomal telomere, two probes within the Pseudoautosomal Region (PAR) common to the X and Y chromosomes, and two Y probes. The results of this study will be presented. It is hoped that this method will replace the labour-intensive FISH analysis and will become routinely incorporated into our diagnostic laboratory thus reducing analysis time and increasing analysis efficiency.

Introduction
============

The two pillars of atherosclerosis are inflammation and dyslipidaemia. Inflammatory cell recruitment and transendothelial migration are mediated by molecules such as intercellular adhesion molecule-1 (ICAM-1) and are crucial for plaque development. There is little information on the role of single nucleotide polymorphisms (SNPs) and haplotype analysis in ICAM-1 in ischaemic heart disease (IHD). We investigated this using an Irish family-based study, where affected individuals had early-onset IHD.

Methods
=======

A total of 1494 individuals from 580 families were included (800 discordant sib-pairs and 64 parent-child trios). Seven markers (SNPs) across the ICAM-1 gene were selected. Linkage disequilibrium (LD) between both the 7 SNPs and resultant haplotypes and disease status was examined using family-based tests of association (combined transmission disequilibrium test and pedigree disequilibrium test).

Results
=======

The number of informative families for the SNPs IC1, IC3, IC4, IC6, IC7, IC8 and IC9 were 117, 275, 278, 271, 264, 132 and 242, respectively. Strong LD between the SNPs was found. No association was detected between any of the 7 marker SNPs or the 3 common haplotypes (frequency \>10%) and IHD.

Conclusions
===========

Haplotype analysis of the ICAM-1 gene using family-based tests has not detected association with IHD within an Irish population.

The failure-to-attend rate in our clinics was found to be 24%. A postal questionnaire was constructed to assess barriers to attendance to clinic. Anonymous surveys were divided by type of referral (counsellor; developmental delay; deafness; clefting; other consultant) to assess difficulties experienced when trying to attend clinics. Questions included difficulties with practical arrangements (time/date/transport), lack of information about the appointment, or concerns about a genetics appointment (insurance/blame). Questionnaires were sent to 83 attenders and 91 non-attenders. 38 responses (46%) were received for attenders and 30 (33%) from non-attenders (4 blank : 3 moved and 1 died). Responses from attenders included : 3/5 clefting, 21/49 other consultant, 5/12 developmental delay, 1/3 deafness, and 8/14 counselling. Responses from non-attenders included : 0/3 clefting, 16/55 other consultant, 2/9 developmental delay, 3/11 deafness and 9/13 counselling. Among attenders, 13 (34%) were afraid of what they would be told and 12 (32%) had issues involving practical arrangements. Among non-attenders, 19 (73%) had issues involving practical arrangements, 5 (19%) were afraid of what they would be told, 4 (15%) did not know why they were referred and 1 (4%) was concerned about payment. Although all participants had received a Genetics information leaflet with their appointment letter, significant numbers from both groups remain concerned about what is said in a Genetics clinic.

Marfan\'s syndrome is a multisystem autosomal dominant disorder characterised by skeletal, ocular and cardiac involvement. Mutations in the fibrillin 1 gene on chromosome 15 have been found in some people with Marfan syndrome. The Ghent clinical diagnostic criteria were agreed and published in 1996.

We reviewed a series of 83 patients referred to the National Centre for Medical Genetics where a clinical diagnosis of Marfan\'s was raised. We determined from which clinicians the referral came, whether the patient fulfilled the Ghent criteria, whether an alternative diagnosis was offered, and whether FBN1 gene analysis was carried out.

Of the 83 index cases, 196 family members were seen. 26 patients (31%) were confirmed to have a clinical diagnosis of Marfan, 3 (4%) had an alternative diagnosis, (65%) did not fulfil the Ghent criteria. FBN1 gene analysis was carried out in 18 patients with clinical Marfan, and of these 2 had a confirmed FBN1 mutation. The final diagnosis of Marfan was more likely when the patient was referred from cardiology or ophthalmology, than paediatrics or primary care.

Only 31% of patients referred had a final diagnosis of Marfan. The diagnosis is still to be made on clinical grounds. The use of the Ghent criteria needs wider dissemination in the medical community.
